Pathologists Quality Registry Update. The College of American Pathologists (CAP) Pathologists Quality Registry once again received approval and its qualified clinical data registry status from the Centers for Medicare & Medicaid Services (CMS). This recognizes the registry’s ability to improve care for patients and collect quality data to submit for the Merit-based Incentive Payment System (MIPS).
The Pathologists Quality Registry reduces pathologists’ burdens when participating in MIPS by providing practice-specific guidance, consolidating reporting for both the Quality and the Improvement Activities categories and providing pathology practices with real-time performance benchmark reports.
The is the CAP’s eighth consecutive year as a qualified clinical data registry (QCDR). The CAP has the oldest pathology QCDR and the only QCDR focused exclusively on supporting pathologists in MIPS. The CAP’s registry is the highest-scoring option for pathologists, with more pathology QCDR measures than any other registry.
To support pathologists, the Pathologists Quality Registry offers pathology-specific quality measures and several data pathway options to report quality measures. The registry will offer 15 pathology quality reporting measures for MIPS, most of which are exclusively available in the Pathologists Quality Registry. This includes three new measures created by the CAP and approved by the CMS to ensure pathologists who participate in the CAP’s Registry can achieve higher scores.
Cancer Statistics 2024. Every year, it's the most-widely cited research paper... the compilation of cancer data that is critical for guiding both current and future research endeavors.
Cancer Statistics 2024, a scientific paper published in the American Cancer Society journal, was released this week. The research shows that breast, prostate, colorectal (ages 0-54), and cervical (ages 30-44) cancers are on the rise. To accompany the paper, the American Cancer Society also released its Cancer Facts & Figures 2024, an educational companion that breaks down the research, including:
- Estimated numbers of new cancer cases and deaths in 2024 by cancer site and US state
- Current cancer incidence, mortality, and survival statistics
- Information on cancer symptoms, risk factors, early detection, and treatment
The 2024 statistics paper highlights the critical need to invest in equitable application of proven cancer control interventions, and in discovery for new therapies -- especially for advanced-stage cancers. It also recommends lowering the screening age for colorectal cancer to 45.
Spring Residents Forum. Registration is now open for the 2024 Spring Residents Forum Meeting.
The CAP's Spring Residents Forum is the leading national meeting dedicated to pathology residents, fellows, and medical students. This event uniquely caters to the diverse challenges and opportunities that define a career path in pathology.
Hear from American Board of Pathology (ABPath) leaders about the future of CBA and CBME in the current medical landscape. Gain a deeper understanding of the CAP Graduate Medical Education Committee's latest efforts regarding Entrustable Professional Activities (EPAs). Gain insights into the current pathology job market, emerging trends, and opportunities—all informed by the latest CAP survey of new job seekers. Interactive breakout sessions will guide attendees through the various career stages in pathology.
The Forum is scheduled for March 23 in Baltimore. Attendees may join the forum virtually or in person. Register online!
Founded in 2002, Voicebrook is the leading provider of reporting solutions for pathology, with more than 550 client sites across the US, Canada, and Australia.
The VoiceOver PRO software application allows pathology professionals to rapidly and accurately create pathology reports, choosing one of three customizable workflows. VoiceOver PRO incorporates speech recognition, digital dictation, customizable templates, and an assortment of input devices, providing direct integration with the user’s Anatomic Pathology (AP) system.